{"id":888612,"date":"2025-09-23T07:48:44","date_gmt":"2025-09-23T11:48:44","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-participate-in-two-upcoming-investor-conferences\/"},"modified":"2025-09-23T07:48:44","modified_gmt":"2025-09-23T11:48:44","slug":"altimmune-to-participate-in-two-upcoming-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-participate-in-two-upcoming-investor-conferences\/","title":{"rendered":"Altimmune to Participate in Two Upcoming Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">GAITHERSBURG, Md., Sept.  23, 2025  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GDxfANDL7MhChqjO1ms6c8xBEwS_aR4oKSdmwtwziCEd3cfkBp9PRAf5IBICjZCBzIU6KnZC4NpIf9_3RCM0Wg==\" rel=\"nofollow\" target=\"_blank\">Altimmune, Inc.<\/a> (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the Company\u2019s management team will participate and be available for 1&#215;1 meetings at the following investor conferences:<\/p>\n<ul type=\"disc\">\n<li>\n          <strong>Stifel 2025 Virtual Cardiometabolic Forum<br \/><\/strong><br \/>\n          <em>Tuesday, September 30, 2025<br \/><\/em><br \/>\n          <em>Fireside Chat at 10:30 a.m. Eastern Time<\/em>\n        <\/li>\n<\/ul>\n<ul type=\"disc\">\n<li>\n          <strong>H.C. Wainwright Liver Disease Virtual Conference<\/strong><br \/>\n          <br \/>\n          <em>Tuesday, October 21, 2025<br \/><\/em><br \/>\n          <em>Fireside Chat at 7:00 a.m. Eastern Time<\/em>\n        <\/li>\n<\/ul>\n<p align=\"justify\">The sessions will be webcast and can be accessed by visiting the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=slKLrmBL4K4DvPx8DP3R9j-y0TRocHYMl7O1QFX63UWUj2_Osb2RAk0Z26Erl-3cD3jnbiq1UHBX8zM7cFE7X3bu4JRo18vvdT02iPQYSeoZLg-SgZitVpQkzZtrrDJ3YTXrA2v1FN_OgpPkXGD13A==\" rel=\"nofollow\" target=\"_blank\">Events<\/a> section of the Altimmune website.<\/p>\n<p align=\"justify\">\n        <strong>About Altimmune<br \/><\/strong>Altimmune is a late clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for liver and cardiometabolic diseases. The Company\u2019s lead product candidate is pemvidutide, a GLP-1\/glucagon dual receptor agonist for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH), Alcohol Use Disorder (AUD), Alcohol-associated Liver Disease (ALD) and obesity. \u00a0For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=oa16sqP5bAGDRl9QpaYzU2W6WsI3kxfwpr_noKZ9wjbtC7-7uZpBMVYXBfpXxjVzWgzdsyS_ih9KL0DzjjyPd4wR0qqMWCw1_Ext_fgw2CFOPNp88LrPlp1T-9QFttZpjjWZ3VdoPCzX0OVIR2drhMwkDvmoZh4997MImyTQHfGfPiQgTVcSDAftskdTmVKbZcavOwKF-KqXg66brn-bVahTaqR3T41DVVi7kGpPqjqNKC5ENpZP-oamXr39wdfyd_mVNB8vBZtq8FqVaRJCSg==\" rel=\"nofollow\" target=\"_blank\">www.altimmune.com<\/a>.<\/p>\n<p>\n        <strong>Follow @Altimmune, Inc. on <\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9Jf0jtwEC8egnNFvVz8mbxRge07vU-x_5Oky1HtNsGaGUfJS8lLaBf9zht1qwsyKz7Z9WMDv3Selm6ABQTyBx2FUkgnfzsZp01JPjGAm_ys=\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <strong>LinkedIn<\/strong><br \/>\n        <\/a><br \/>\n        <br \/>\n        <strong>Follow @AltimmuneInc on <\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=l8_CD8lfEFXJeVTDG16EAAlIsA1T_XGdIR7YJ17TbiZhWva-i9sCSGZBQZS8Lut_yukzta0MKCo5sC9tSnmkRA==\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <strong>X<\/strong><br \/>\n        <\/a>\n      <\/p>\n<p>\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>Lee Roth<br \/>Burns McClellan<br \/>Phone: 646-382-3403<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=oDbGGsYxXpn8rzCfE7ilz0JhfIII0ufECyHMqwpYDfECJa9xZ4fiP8uXTid49FlHhCVxnN6OgUuOuSTYYrT0SjJQZNlER142n3__3eoh_cA=\" rel=\"nofollow\" target=\"_blank\">lroth@burnsmc.com<\/a><\/p>\n<p>This press release was published by a CLEAR\u00ae Verified individual.<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzMzQxNiM3MTU5NzMxIzIwMTA2NzY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/M2Y0YmI3NjMtOTdmOS00MjQxLWE4ZDAtZDk0MWNkNGYxMWVhLTEwMjIyNDktMjAyNS0wOS0yMy1lbg==\/tiny\/Altimmune-Inc.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>GAITHERSBURG, Md., Sept. 23, 2025 (GLOBE NEWSWIRE) &#8212; Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the Company\u2019s management team will participate and be available for 1&#215;1 meetings at the following investor conferences: Stifel 2025 Virtual Cardiometabolic Forum Tuesday, September 30, 2025 Fireside Chat at 10:30 a.m. Eastern Time H.C. Wainwright Liver Disease Virtual Conference Tuesday, October 21, 2025 Fireside Chat at 7:00 a.m. Eastern Time The sessions will be webcast and can be accessed by visiting the Events section of the Altimmune website. About AltimmuneAltimmune is a late clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for liver and cardiometabolic diseases. The Company\u2019s &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-participate-in-two-upcoming-investor-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Altimmune to Participate in Two Upcoming Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-888612","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Altimmune to Participate in Two Upcoming Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-participate-in-two-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Altimmune to Participate in Two Upcoming Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"GAITHERSBURG, Md., Sept. 23, 2025 (GLOBE NEWSWIRE) &#8212; Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the Company\u2019s management team will participate and be available for 1&#215;1 meetings at the following investor conferences: Stifel 2025 Virtual Cardiometabolic Forum Tuesday, September 30, 2025 Fireside Chat at 10:30 a.m. Eastern Time H.C. Wainwright Liver Disease Virtual Conference Tuesday, October 21, 2025 Fireside Chat at 7:00 a.m. Eastern Time The sessions will be webcast and can be accessed by visiting the Events section of the Altimmune website. About AltimmuneAltimmune is a late clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for liver and cardiometabolic diseases. The Company\u2019s &hellip; Continue reading &quot;Altimmune to Participate in Two Upcoming Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-participate-in-two-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-23T11:48:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzMzQxNiM3MTU5NzMxIzIwMTA2NzY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-participate-in-two-upcoming-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-participate-in-two-upcoming-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Altimmune to Participate in Two Upcoming Investor Conferences\",\"datePublished\":\"2025-09-23T11:48:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-participate-in-two-upcoming-investor-conferences\\\/\"},\"wordCount\":191,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-participate-in-two-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUzMzQxNiM3MTU5NzMxIzIwMTA2NzY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-participate-in-two-upcoming-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-participate-in-two-upcoming-investor-conferences\\\/\",\"name\":\"Altimmune to Participate in Two Upcoming Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-participate-in-two-upcoming-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-participate-in-two-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUzMzQxNiM3MTU5NzMxIzIwMTA2NzY=\",\"datePublished\":\"2025-09-23T11:48:44+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-participate-in-two-upcoming-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-participate-in-two-upcoming-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-participate-in-two-upcoming-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUzMzQxNiM3MTU5NzMxIzIwMTA2NzY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUzMzQxNiM3MTU5NzMxIzIwMTA2NzY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-participate-in-two-upcoming-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Altimmune to Participate in Two Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Altimmune to Participate in Two Upcoming Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-participate-in-two-upcoming-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Altimmune to Participate in Two Upcoming Investor Conferences - Market Newsdesk","og_description":"GAITHERSBURG, Md., Sept. 23, 2025 (GLOBE NEWSWIRE) &#8212; Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the Company\u2019s management team will participate and be available for 1&#215;1 meetings at the following investor conferences: Stifel 2025 Virtual Cardiometabolic Forum Tuesday, September 30, 2025 Fireside Chat at 10:30 a.m. Eastern Time H.C. Wainwright Liver Disease Virtual Conference Tuesday, October 21, 2025 Fireside Chat at 7:00 a.m. Eastern Time The sessions will be webcast and can be accessed by visiting the Events section of the Altimmune website. About AltimmuneAltimmune is a late clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for liver and cardiometabolic diseases. The Company\u2019s &hellip; Continue reading \"Altimmune to Participate in Two Upcoming Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-participate-in-two-upcoming-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2025-09-23T11:48:44+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzMzQxNiM3MTU5NzMxIzIwMTA2NzY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-participate-in-two-upcoming-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-participate-in-two-upcoming-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Altimmune to Participate in Two Upcoming Investor Conferences","datePublished":"2025-09-23T11:48:44+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-participate-in-two-upcoming-investor-conferences\/"},"wordCount":191,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-participate-in-two-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzMzQxNiM3MTU5NzMxIzIwMTA2NzY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-participate-in-two-upcoming-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-participate-in-two-upcoming-investor-conferences\/","name":"Altimmune to Participate in Two Upcoming Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-participate-in-two-upcoming-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-participate-in-two-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzMzQxNiM3MTU5NzMxIzIwMTA2NzY=","datePublished":"2025-09-23T11:48:44+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-participate-in-two-upcoming-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-participate-in-two-upcoming-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-participate-in-two-upcoming-investor-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzMzQxNiM3MTU5NzMxIzIwMTA2NzY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzMzQxNiM3MTU5NzMxIzIwMTA2NzY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-participate-in-two-upcoming-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Altimmune to Participate in Two Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/888612","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=888612"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/888612\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=888612"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=888612"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=888612"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}